FDA’s approval on May 23 of Durata Therapeutics Inc.’s antibiotic Dalvance (dalbavancin) underscores the potential and also the challenges life science companies face in grappling with new payment and ...
(Reuters) - Generic drugmaker Actavis Plc said it would acquire Durata Therapeutics Inc in a deal valued at about $675 million to bolster its infectious disease portfolio. Durata's shares were trading ...
CINNCINNATI, OH — A newly published case report describes a single incident where the Durata (St Jude Medical, St Paul, MN) lead failed at the time of high-voltage shock delivery in a patient with an ...
DENVER, CO — An independent analysis of three registries run by St Jude Medical saw vanishingly low rates of mechanical failure of the company's implantable defibrillator leads insulated with the ...
Buyout-hungry Actavis ($ACT)--which is alternatively spotlighted as both a buyer and a possible buyout target--has snapped up Chicago-based Durata Therapeutics ($DRTX ...
Actavis plans to acquire Durata Therapeutics for $675 million-plus, the companies said today, in a deal that broadens the buyer’s portfolio with the already-marketed infectious disease drug Dalvance™ ...
St. Jude's Durata leads are back in the spotlight after a journal article detailed a case of mechanical failure.--Courtesy of St. Jude Medical A new report of a ...
Experienced Development and Commercial Team Bolsters Actavis' Infectious Disease Expertise Leverages Actavis' Hospital Sales and Marketing Capabilities DUBLIN, Ireland and CHICAGO, Oct. 6, 2014 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results